SCHEMBL18600154

SCHEMBL18600154

C#CCN(Cc1ccc(F)cc1)c1ccc(NC(=O)OC)c(C)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.78
CYP2C8 P10632 1/20 0.78
CYP2B6 P20813 1/20 0.78
KCNQ4 P56696 4/20 0.72
KCNQ2 O43526 1/20 0.68
KCNQ5 Q9NR82 3/20 0.68
MAPT P10636 5/20 0.45
GFER P55789 3/20 0.45
MAPK1 P28482 3/20 0.45
ALDH1A1 P00352 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 3/20 0.42
HSD17B10 Q99714 2/20 0.42
ALOX15 P16050 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23969467 0.92 CYP1A2 (0.67) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2
SCHEMBL16233333 0.92 KCNQ4 (0.86) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2
SCHEMBL15996913 0.91 KCNQ4 (0.82) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2
SCHEMBL15996918 0.90 KCNQ4 (0.70) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2
SCHEMBL15996931 0.88 KCNQ2 (0.83) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2
SCHEMBL18600189 0.88 KCNQ4 (0.68) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2
SCHEMBL18575306 0.88 CYP1A2 (1.00) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2
SCHEMBL15996895 0.88 KCNQ4 (0.70) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2
Hydrochloric Acid SCHEMBL18575310 0.87 CYP1A2 (0.98) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2
SCHEMBL18600350 0.86 KCNQ4 (0.66) CYP1A2CYP2C8CYP2B6KCNQ4KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3138833-B1 NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2021-11-03 EP disclosed
US-10316008-B2 KCNQ potassium channel agonist, and preparation method therefor and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-06-11 US disclosed
US-20180134677-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2018-05-17 US disclosed
US-20170081301-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONISTS, METHOD OF PREPARATION AND METHOD OF USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2017-03-23 US disclosed
EP-3138833-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2017-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134677-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF KCNQ5, KCNQ4, KCNQ1 CYP1A2 1348/4885CYP2C8 1692/4885CYP2B6 1423/4885
US-10316008-B2 KCNQ potassium channel agonist, and preparation method therefor and use thereof KCNQ5, KCNQ4, KCNQ3 CYP1A2 1139/4885CYP2C8 1423/4885CYP2B6 1397/4885
US-20170081301-A1 NOVEL KCNQ POTASSIUM CHANNEL AGONISTS, METHOD OF PREPARATION AND METHOD OF USE THEREOF KCNQ5, KCNQ4, KCNQ3 CYP1A2 950/4885CYP2C8 1512/4885CYP2B6 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.